Aliskiren + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Decompensated Heart Failure
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Trial Timeline
May 1, 2009 → Aug 1, 2012
NCT ID
NCT00894387About Aliskiren + Placebo
Aliskiren + Placebo is a phase 3 stage product being developed by Novartis for Acute Decompensated Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00894387. Target conditions include Acute Decompensated Heart Failure, Congestive Heart Failure.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01437943 | Approved | Terminated |
| NCT01067326 | Phase 3 | Terminated |
| NCT01417104 | Phase 2/3 | Terminated |
| NCT00982033 | Approved | Completed |
| NCT00894387 | Phase 3 | Completed |
| NCT00768040 | Phase 2 | Terminated |
| NCT00549757 | Phase 3 | Terminated |
| NCT00414609 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Decompensated Heart Failure